Animas announced that the Food and Drug Administration (FDA) has approved the Animas Vibe insulin pump and continuous glucose monitoring system for the management of insulin-dependent diabetes in adults ages ≥18.

Animas Vibe is the first integrated system that features Dexcom G4 PLATINUM sensing technology with a 13% mean absolute relative difference (ARD) for highly accurate results.

Patients can view glucose data and administer insulin directly from the pump, which aids them in adjusting insulin delivery and overall diabetes management. The high-contrast color pump screen displays the patient’s glucose highs, lows, and rates of change over time. The complete glucose monitoring system obtains glucose measurements every five minutes to provide real-time values and glucose patterns.

RELATED: Insulin Dependence Ups Post-Op Complication Risk

Animas Vibe allows insulin dosing in basal increments of 0.025U/hr across all ranges (0.025–25.00U/hr) and a bolus increments in 0.05U across all ranges (0.05–35U). Insulin dosing can be personalized by choosing individual insulin-to-carb ratios, insulin sensitivity factors, and blood glucose targets in 30-minute increments.

Animas Vibe is approved for up to seven days of continuous wear and is waterproof up to 12 feet for up to 24 hours; the Dexcom G4 PLATINUM transmitter is water resistant up to eight feet for 24 hours.

Shipments of Animas Vibe are anticipated to begin in January 2015.

For more information call (877) 937-7867 or visit